Pixelgen Technologies Unveils Nanoscale Proximity Network Assay for Analyzing Protein Interactomics of Single Cells, Launches New Product Line

The Pixelgen Proxiome Kit offers the next omics dimension for single cells, protein interactomics

STOCKHOLM, Sweden and MARCO ISLAND, Fla., Feb. 24, 2025 -- Pixelgen Technologies today unveiled a novel technology for exploring the dynamic protein interactome at the single cell level, building on its earlier technological innovations in DNA-based 3D proteomics. The Proximity Network Assay delivers nanoscale spatial analysis of immune cell proteins at scale. The new technology underpins the Pixelgen Proxiome Kit, which launched today as the first kit in a new product line offering researchers the highest resolution of single cellular analyses by providing a new omics dimension for novel insights into disease mechanisms, drug response, biomarker discovery, and more.

"The dynamic protein interactions of a cell are vastly understudied because our tools to explore them lack the resolution and capacity to be effective in modern omics-scale studies. Our team of scientists, computational biologists, and software engineers has just changed that, and we're extremely excited today to share an innovation we believe will ultimately lead to breakthroughs in cancer, hematology, immunology, and cell therapy research," said Pixelgen CEO and co-founder Simon Fredriksson. "This technology will also enable future product development for analyzing cell communication in immune synapses and intracellular signaling pathways, for single cells and across tissues."

At this stage of scientific discovery, new advancements will center around our understanding of proteins. Proteins do not act alone but as spatial constellations and interactions controlling the activities and functions of cells. The protein interactome represents the network of these functional interactions between proteins that drive essential biological processes, such as signal transduction, migration, metabolism, gene regulation, and immune responses. The Proximity Network Assay at the core of the Pixelgen Proxiome Kit allows researchers to study protein interactomics at an unprecedented scale.

The Pixelgen Proxiome Kit, Immuno 155 uses the Proximity Network Assay, a DNA-based chemistry where each target and its neighbors in close proximity are assigned a unique spatial position across single cells at an average resolution of 50 nanometers. Its validated protein panel contains 155 immune cell surface protein targets to produce a detailed map of up to 50,000 proteins per cell, illuminating cell surface protein abundance, clustering, and colocalization. The Pixelgen Proxiome Kit is instrument-free and easy-to-use, analogous to a sample-prep kit for NGS, and supports cells in suspension from PBMCs, BM, cell lines, and dissociated organoids.

"I am thrilled to have had the chance to use the Pixelgen Proxiome Kit. The changes I observed in immune cell protein Proximity Networks gave high-resolution insights to my research," said geneticist Christopher Mason, Ph.D.

The Proximity Network Assay uses DNA barcoded antibodies and rolling circle amplification, with the addition of proximity oligos and a gapfill-ligation reaction, to form multiple connections between neighboring proteins. The molecules are then sequenced to create a nanoscale protein Proximity Network for each cell, which is analyzed using spatial statistics to define the organization of each cell's protein interactome and cell-cell complexes.

About Pixelgen Technologies
Pixelgen Technologies AB is on a mission to deliver biology at the highest resolution by understanding the molecular basis of cellular function with new tools and technologies that decipher the protein interactomics of single cells in unprecedented ways. The company's patented Proximity Network Assay delivers nanoscale spatial analysis of immune cell proteins at ultra-high capacity and underpins the Pixelgen Proxiome Kit for precision medicine. A foundational technology, the Proximity Network Assay will power a portfolio of products for translational research to accelerate advances in immunology, hematology, and cell therapy. Pixelgen was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs and is venture-backed.

Contacts

Corporate:
Annika Branting
annika.branting@pixelgen.com
+46 762-69 68 46

Media:
Susan Thomas
susan@endpointcommunications.net
+1 (619) 540-9195

This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.